A BRAF mutation is a change in the BRAF gene that causes cells to grow and divide uncontrollably, playing a direct role in several types of cancer. About 4% of all cancer patients carry a BRAF mutation, with the highest rates found in melanoma (roughly 40% of cases) and thyroid cancer (about 33%). Understanding this mutation matters because it opens the door to targeted therapies designed to block the specific protein driving tumor growth.
What the BRAF Gene Normally Does
The BRAF gene provides instructions for making a protein that acts as a relay switch inside your cells. When a cell receives a growth signal from outside, the BRAF protein passes that signal along a chain of proteins until it reaches the cell’s nucleus, where genes for growth and division get switched on. This relay system is called the RAS/MAPK pathway, and it controls some of the most fundamental things a cell does: growing, dividing, maturing into a specialized cell type, migrating to a new location, and even self-destructing when something goes wrong.
Under normal conditions, the BRAF protein flips on when a growth signal arrives and flips back off when the signal stops. That on-off cycling keeps cell growth tightly controlled. The pathway is especially active during development before birth, when rapid, coordinated cell growth is essential for building tissues and organs.
How the Mutation Changes Cell Behavior
When the BRAF gene mutates at a specific spot, the protein it produces gets locked in the “on” position permanently. The most common version, called V600E, involves a single amino acid swap: valine gets replaced by glutamic acid at position 600 in the protein chain. This tiny change forces the protein’s internal structure into its active shape, so it no longer needs an upstream signal to start firing.
The result is dramatic. The mutated BRAF protein is roughly 500 times more active than the normal version. It continuously pushes signals down the MAPK pathway, telling the cell to keep dividing regardless of whether the body actually needs new cells. The normal checks and balances that prevent uncontrolled growth are effectively bypassed. In melanoma, for instance, this constant signaling transforms normal pigment-producing cells into cancer cells.
Unlike the normal BRAF protein, which only works when paired with a partner protein, the V600E mutant can function on its own as a single unit. This distinction turns out to be important for treatment, because drugs can be designed to target the lone-wolf mutant protein while leaving paired normal proteins relatively undisturbed.
Which Cancers Carry BRAF Mutations
BRAF mutations appear across a range of cancer types, but the frequency varies widely. In a genomic database of over 114,000 cancer patients, the highest rates were found in melanoma (39.7% of cases), thyroid cancer (33.3%), and small intestinal cancers (8.9%). In terms of raw numbers, colorectal cancer and non-small cell lung cancer also account for large shares of BRAF-mutant tumors simply because those cancers are so common overall.
The V600E variant dominates, making up about 62% of all BRAF mutations detected across cancers. But there are other classes. Class II mutations account for roughly 16.5% of cases and Class III mutations for about 17.7%. These different classes behave differently at the molecular level and can influence which treatments work best.
V600E vs. V600K: Not All Variants Are Equal
The second most common variant in melanoma, V600K, swaps valine for a different amino acid (lysine instead of glutamic acid). While V600E and V600K tumors look the same under a microscope and share identical clinical features on the skin, their behavior diverges in important ways. V600K melanomas tend to appear in older patients (average age 66, compared to 58 for V600E) and show a stronger association with chronic sun damage, particularly on the head and neck.
More critically, V600K tumors appear to be more aggressive. They carry a higher risk of spreading to the brain and lungs, progress faster from diagnosis to metastasis, and show significantly greater resistance to targeted therapies. In clinical comparisons, patients with V600E mutations were more likely to achieve a stable response to treatment, while V600K patients more often had partial or no response. There is no way to distinguish between the two variants based on appearance alone, so molecular testing is essential.
How BRAF Mutations Are Detected
Testing for a BRAF mutation typically starts with a tissue biopsy, which remains the gold standard. A sample of tumor tissue is analyzed using molecular techniques that can identify the specific genetic change present. Next-generation sequencing, which reads large stretches of DNA at once, can detect BRAF mutations along with other relevant genetic alterations in a single test. Liquid biopsy, which looks for tumor DNA circulating in the blood, is an emerging alternative that avoids the need for a tissue sample, though clinical decisions are still primarily based on tissue results.
Your oncologist will generally order BRAF testing at the time of diagnosis for cancers where the mutation is common, particularly advanced melanoma and metastatic colorectal cancer. Knowing whether a BRAF mutation is present, and which variant it is, directly shapes treatment decisions.
Targeted Therapy for BRAF-Mutant Cancers
The discovery of BRAF mutations opened an entirely new treatment approach: drugs that specifically block the overactive BRAF protein. These are used in combination with a second drug that blocks MEK, the next protein in the signaling chain. Hitting the pathway at two points simultaneously works better than targeting BRAF alone and helps delay resistance.
Three combination regimens are currently approved for BRAF-mutant melanoma. In a landmark trial published in the New England Journal of Medicine, patients with metastatic melanoma treated with a BRAF-MEK combination as their first therapy had a 5-year overall survival rate of 34%, with 19% remaining progression-free at five years. By comparison, patients treated with a single BRAF-blocking drug had 5-year survival rates of only 23 to 27%. Immunotherapy combinations have shown even higher long-term survival in some studies, with 5-year rates reaching 43 to 53% depending on the regimen, so treatment selection involves weighing targeted therapy against immunotherapy or sequencing the two.
BRAF-targeted treatment has also expanded beyond melanoma. In December 2024, the FDA granted accelerated approval for a BRAF-targeted combination for metastatic colorectal cancer carrying the V600E mutation, reflecting the growing role of mutation-guided treatment across cancer types.
Side Effects of BRAF-Targeted Treatment
Combination therapy is generally tolerable, but side effects are common and vary depending on which drug pair is used. Fever is the most frequent issue with one common combination, affecting about 43% of patients at mild to moderate severity. Diarrhea is the hallmark side effect of another pairing, occurring in over half of patients. Fatigue, joint pain, skin rash, nausea, and vomiting are also frequently reported across regimens.
Severe side effects occur less often but include significant rash, high blood pressure (in about 6 to 8% of patients), and liver inflammation detectable through blood tests. Dose reductions are common, applied in roughly 28 to 65% of patients depending on the regimen. About one in four patients on certain combinations ultimately discontinue treatment due to side effects. Most mild to moderate side effects are manageable with dose adjustments or temporary treatment pauses.
Why Resistance Develops
Most BRAF-mutant cancers eventually find a way around targeted therapy, which is why long-term progression-free survival remains a challenge. The tumor cells adapt through several mechanisms. One of the most common is “RAF isoform switching,” where cells stop relying on the blocked BRAF protein and instead activate related proteins (CRAF or ARAF) to keep the same growth-signaling pathway running. It is essentially a detour around the roadblock.
Tumors can also activate entirely different signaling routes. Some ramp up a parallel survival pathway called PI3K, bypassing the MAPK pathway altogether. Others increase the activity of certain cell-surface receptors that feed into these alternative pathways. These diverse resistance mechanisms explain why adding a MEK-blocking drug helps but does not fully solve the problem, and why researchers continue working on strategies to block multiple escape routes simultaneously.